# Clinical Trials Data EGFR - Document 14

# COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01596790

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Age \\> 18 years\n\* Colon or rectum adenocarcinoma (based on the histology)\n\* Visceral metastases (synchronous and/or metachronous)\n\* Metastatic disease measurable with the RECIST 1.1 criteria\n\* WHO performance status 0, 1 or 2\n\* Life expectancy\\>3 months when starting the treatment\n\* Chemotherapy in metastatic 1rst line combining a protocol of conventional chemotherapy combining 5-FU and IRINOTECAN (FOLFIRI, XELIRI) associated with bevacizumab\n\* Follow-up of at least one year\n\* Collection of the written consent\n\* Social security affiliation\n\nExclusion Criteria:\n\n\* 2nd line chemotherapy and beyond\n\* History of other cancers considered not cured\n\* Active and progressive infection or other serious disease that may not allow the patient to receive the treatment\n\* refusal to participate\n\* Patient unable to express his consent\n\* Pregnant women\n\* Patient unable to be followed-up for at least one year\n\* Current participation to another clinical trial\n\* Patients under guardianship\n\* Vulnerable people protected by the law",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, there is no mention of an EGFR gene mutation as either an inclusion or exclusion criterion. The trial criteria focus on factors such as diagnosis (colon or rectum adenocarcinoma), metastatic disease, treatment protocol (specifically involving chemotherapy with 5-FU and IRINOTECAN, and bevacizumab), performance status, life expectancy, consent, etc.   
  
Given the information available, a patient with an EGFR gene mutation would not be automatically excluded from the trial. The mutation, in itself, does not appear to be a factor that affects eligibility according to the criteria you provided. However, it's always important for a patient to discuss with the trial team and their healthcare provider, as there may be additional considerations or updates not captured by this list.